- Senate passes Drug Quality and Security Act
- Crossmark names Janet Carter-Smith VP
- FDA to allow dispensing of GSK's Type 2 diabetes drug Avandia in retail pharmacies again
- FDA approves combination of two GSK drugs for skin cancer
- 21 health industry groups address FDA on proposed changes to generic drug label rules
PHILADELPHIA — GlaxoSmithKline has changed prescribing information on the labeling for one of its Type 2 diabetes drugs to reflect new restrictions on the drug’s use, the drug maker said.
GSK said it revised the labeling for Avandia (rosiglitazone) to take into account the risks of heart attacks and heart failure in patients taking the drug.
The FDA moved to restrict access to Avandia last year and required GSK to create a risk evaluation and mitigation strategy for the drug.